- Home
- SCYX vs NYC Comparison
SCYX vs NYC Comparison
Compare SCYX & NYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCYX | NYC |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6M | 25.4M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | SCYX | NYC |
|---|---|---|
| Price | $0.66 | $7.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 563.4K | 5.1K |
| Earning Date | 11-05-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,932,000.00 | ★ $51,688,000.00 |
| Revenue This Year | $167.73 | $8.40 |
| Revenue Next Year | $290.78 | $1.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $7.03 |
| 52 Week High | $1.49 | $16.30 |
Technical Indicators
Market Signals| Indicator | SCYX | NYC |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 35.57 |
| Support Level | $0.65 | $7.03 |
| Resistance Level | $0.72 | $7.85 |
| Average True Range (ATR) | 0.05 | 0.47 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 54.91 | 17.77 |
Price Performance
Historical ComparisonAbout SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.